En undersøgelse af KT-621 administreret oralt til voksne deltagere med moderat til svær eosinofil astma (BREADTH)
En fase 2b, randomiseret, dobbeltblind, placebo-kontrolleret, parallel-gruppe, multicentret, dosisundersøgende undersøgelse af effektiviteten og sikkerhedsprofilen for KT-621 administreret oralt til voksne deltagere med ukontrolleret moderat til svær eosinofil astma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Kymera Medical Director
- Telefonnummer: 857-285-5300
- E-mail: clinicaltrials@kymeratx.com
Studiesteder
-
-
-
Buenos Aires, Argentina
- Rekruttering
- Kymera Investigative Site
-
Concepción del Uruguay, Argentina
- Rekruttering
- Kymera Investigative Site
-
Lobos, Argentina
- Rekruttering
- Kymera Investigative Site
-
Mar del Plata, Argentina
- Rekruttering
- Kymera Investigative Site
-
Quilmes, Argentina
- Rekruttering
- Kymera Investigative Site
-
Rosario, Argentina
- Rekruttering
- Kymera Investigative Site
-
San Miguel de Tucumán, Argentina
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Brussels, Belgien
- Rekruttering
- Kymera Investigative Site
-
Erpent, Belgien
- Rekruttering
- Kymera Investigative Site
-
Ghent, Belgien
- Rekruttering
- Kymera Investigative Site
-
Liège, Belgien
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Bedford, Det Forenede Kongerige, MK40 2FG
- Rekruttering
- Kymera Investigative Site
-
Birmingham, Det Forenede Kongerige
- Rekruttering
- Kymera Investigative Site
-
Bristol, Det Forenede Kongerige
- Rekruttering
- Kymera Investigative Site
-
Leicester, Det Forenede Kongerige
- Rekruttering
- Kymera Investigative Site
-
London, Det Forenede Kongerige
- Rekruttering
- Kymera Investigative Site
-
Wythenshawe, Det Forenede Kongerige
- Rekruttering
- Kymera Investigative Site
-
-
-
-
California
-
Lancaster, California, Forenede Stater, 93534
- Rekruttering
- Kymera Investigative Site
-
Long Beach, California, Forenede Stater, 90815
- Rekruttering
- Kymera Investigative Site
-
Northridge, California, Forenede Stater, 91324
- Rekruttering
- Kymera Investigative Site
-
Redding, California, Forenede Stater, 96001
- Rekruttering
- Kymera Investigative Site
-
San Francisco, California, Forenede Stater, 94112
- Rekruttering
- Kymera Investigative Site
-
Upland, California, Forenede Stater, 91786
- Rekruttering
- Kymera Investigative Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Kymera Investigative Site
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06519
- Rekruttering
- Kymera Investigative Site
-
-
Florida
-
Loxahatchee Groves, Florida, Forenede Stater, 33470
- Rekruttering
- Kymera Investigative Site
-
Miami, Florida, Forenede Stater, 33126
- Rekruttering
- Kymera Investigative Site
-
Miami, Florida, Forenede Stater, 33173
- Rekruttering
- Kymera Investigative Site
-
Miami Lakes, Florida, Forenede Stater, 33014
- Rekruttering
- Kymera Investigative Site
-
Orlando, Florida, Forenede Stater, 32819
- Rekruttering
- Kymera Investigative Site
-
Tampa, Florida, Forenede Stater, 33607
- Rekruttering
- Kymera Investigative Site
-
-
Georgia
-
East Point, Georgia, Forenede Stater, 30344
- Rekruttering
- Kymera Investigative Site
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- Kymera Investigative Site
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- Kymera Investigative Site
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40217
- Rekruttering
- Kymera Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Kymera Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27517
- Rekruttering
- Kymera Investigative Site
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Kymera Investigative Site
-
-
Ohio
-
Toledo, Ohio, Forenede Stater, 43617
- Rekruttering
- Kymera Investigative Site
-
-
Oklahoma
-
Edmond, Oklahoma, Forenede Stater, 73034
- Rekruttering
- Kymera Investigative Site
-
-
Oregon
-
Clackamas, Oregon, Forenede Stater, 97015
- Rekruttering
- Kymera Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- Rekruttering
- Kymera Investigative Site
-
Pittsburgh, Pennsylvania, Forenede Stater, 15241
- Rekruttering
- Kymera Investigative Site
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- Kymera Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, Forenede Stater, 29406
- Rekruttering
- Kymera Investigative Site
-
Rock Hill, South Carolina, Forenede Stater, 29732
- Rekruttering
- Kymera Investigative Site
-
-
Tennessee
-
Chattanooga, Tennessee, Forenede Stater, 37403
- Rekruttering
- Kymera Investigative Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75209
- Rekruttering
- Kymera Investigative Site
-
Dallas, Texas, Forenede Stater, 75246
- Rekruttering
- Kymera Investigative Site
-
McKinney, Texas, Forenede Stater, 75069
- Rekruttering
- Kymera Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Rome, Italien
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Bialystok, Polen
- Rekruttering
- Kymera Investigative Site
-
Gdansk, Polen
- Rekruttering
- Kymera Investigative Site
-
Lodz, Polen
- Rekruttering
- Kymera Investigative Site
-
Poznan, Polen
- Rekruttering
- Kymera Investigative Site
-
Sosnowiec, Polen
- Rekruttering
- Kymera Investigative Site
-
Tarnów, Polen
- Rekruttering
- Kymera Investigative Site
-
Trzebnica, Polen
- Rekruttering
- Kymera Investigative Site
-
Wroclaw, Polen
- Rekruttering
- Kymera Investigative Site
-
Zawadzkie, Polen
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Brasov, Rumænien
- Rekruttering
- Kymera Investigative Site
-
Craiova, Rumænien
- Rekruttering
- Kymera Investigative Site
-
Timișoara, Rumænien
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Rekruttering
- Kymera Investigative Site
-
Belgrade, Serbien
- Rekruttering
- Kymera Investigative Site
-
Kamenitz, Serbien, 21204
- Rekruttering
- Kymera Investigative Site
-
Užice, Serbien, 31000
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Bardejov, Slovakiet
- Rekruttering
- Kymera Investigative Site
-
Košice, Slovakiet
- Rekruttering
- Kymera Investigative Site
-
Spišská Nová Ves, Slovakiet
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Cadiz, Spanien
- Rekruttering
- Kymera Investigative Site
-
Jerez de la Frontera, Spanien
- Rekruttering
- Kymera Investigative Site
-
Madrid, Spanien
- Rekruttering
- Kymera Investigative Site
-
Mataró, Spanien
- Rekruttering
- Kymera Investigative Site
-
Santander, Spanien
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Gyeonggi-do, Sydkorea
- Rekruttering
- Kymera Investigative Site
-
Seoul, Sydkorea
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Berlin, Tyskland
- Rekruttering
- Kymera Investigative Site
-
Leipzig, Tyskland
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Vienna, Østrig
- Rekruttering
- Kymera Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.
- Must have a physician diagnosis of asthma for at least 1 year prior to the Screening visit.
- Must be on a stable regimen of medium- to high- dose inhaled corticosteroid (ICS), in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medications used for at least 12 weeks, at a stable dose and regimen, with no change in the dose or frequency of administration for at least 4 weeks prior to the Screening visit and between the Screening and Baseline visits.
- Must have a pre-bronchodilator FEV1 40 to 80% of predicted normal at the Screening and Baseline visits, prior to randomization.
- Must have an ACQ-5 score ≥ 1.5 at the Screening and Baseline visits, prior to randomization.
- Must have a FeNO level of ≥ 25 ppb at the Screening and Baseline visits.
- Must have a demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL at Screening.
- Must have an absolute blood eosinophil count must be ≥ 0.30 × 10^9/L at Screening.
- Must have a documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening.
- Must agree to contraceptive requirements in compliance with the clinical study and local requirements.
- Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
Exclusion Criteria:
- Must not have any clinically significant pulmonary disease other than asthma.
- Must not have had an asthma exacerbation, requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit up to and including the Baseline visit.
- Must not have any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and/or study procedures.
- Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
- Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
- Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
- Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
- Must not be a current smoker of nicotine/tobacco as well as non-nicotine products, have a smoking history of ≥ 10 pack years, or use vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit.
- Must not have a known sensitivity to any of the components of KT-621.
- Must not be a member of the investigational team or his/her immediate family.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Gruppe 1: KT-621 Dosis 1
|
Oral drug |
|
Eksperimentel: Gruppe 2: KT-621 Dosis 2
|
Oral drug |
|
Eksperimentel: Gruppe 3: KT-621 Dosis 3
|
Oral drug |
|
Placebo komparator: Gruppe 4: Placebo
|
Oral placebo matched to KT-621 |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i præ-bronkodilator FEV1
Tidsramme: Fra baseline til uge 12
|
Fra baseline til uge 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i post-bronkodilator FEV1
Tidsramme: Fra baseline til uge 12
|
Fra baseline til uge 12
|
|
Ændring fra baseline i Asthma Control Questionnaire 5-spørgsmålsversion (ACQ-5) score
Tidsramme: Fra baseline til uge 12
|
Fra baseline til uge 12
|
|
Ændring fra baseline i Standardiseret Astma Livskvalitets Spørgeskema [AQLQ(S)] Global Score
Tidsramme: Fra baseline til uge 12
|
Fra baseline til uge 12
|
|
Hyppighed af behandlingsrelaterede bivirkninger (TEAEs)
Tidsramme: Fra baseline gennem uge 16
|
Fra baseline gennem uge 16
|
|
Hyppigheden af behandlingsrelaterede alvorlige bivirkninger (SAE'er)
Tidsramme: Fra baseline gennem uge 16
|
Fra baseline gennem uge 16
|
|
Plasmakoncentration af KT-621 afledt fra plasmakoncentrationstidsdata
Tidsramme: Fra baseline til uge 16
|
Fra baseline til uge 16
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- KT621-AS-202
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .